Basics BridgeBio Pharma, Inc. IPO Date: June 24, 2019 Sector: Healthcare Industry: Biotech Market Cap: $10.2B Activated in VL: True Average Daily Range Avg Daily Range: $0.84 | 3.08% Avg Daily Range (30 D): $1.02 | 2.10% Avg Daily Range (90 D): $0.80 | 1.88% Institutional Daily Volume Avg Daily Volume: 1.45M Avg Daily Volume (30 D): 2.37M Avg Daily Volume (90 D): 2.52M Trade Size Avg Trade Size (Sh.): 85 Avg Trade Size (Sh.) (30 D): 67 Avg Trade Size (Sh.) (90 D): 70 Institutional Trades Total Inst.Trades: 6,495 Avg Inst. Trade: $2.95M Avg Inst. Trade (30 D): $3.75M Avg Inst. Trade (90 D): $3.5M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 4 Market Closing Trades Avg Closing Trade: $6.63M Avg Closing Trade (30 D): $15.21M Avg Closing Trade (90 D): $15.92M Avg Closing Volume: 244.71K     News Sep 6, 2025 @ 6:30 PM Encaleret Showed Parathyroid Hormone-Independent N... Source: Bridgebio Pharma, Inc. Aug 30, 2025 @ 11:15 AM Acoramidis Demonstrates Statistically Significant ... Source: Bridgebio Pharma, Inc. Aug 6, 2025 @ 11:33 AM Helix Acquisition Corp. II Retains More than 60% o... Source: Globe Newswire Jul 9, 2025 @ 2:58 PM KRAS Inhibitors Market Size Clinical Trials Patent... Source: Globe Newswire May 2, 2025 @ 9:04 PM Alnylam Delivers Q1 Surprise, Analysts Highlight A... Source: Vandana Singh Financials   TTM Q2 2025 Q1 2025 Basic EPS $-4.12 $-.95 $-.88 Diluted EPS $-4.12 $-.95 $-.88 Revenue $ 235.81M $ 110.57M $ 116.63M Gross Profit $ 226.84M $ 106.91M $ 113.99M Net Income / Loss $ -785.01M $ -183.76M $ -169.61M Operating Income / Loss $ -656.43M $ -134.28M $ -104.37M Cost of Revenue $ 8.97M $ 3.65M $ 2.64M Net Cash Flow $ 201.59M $ 208.36M $ -140.5M PE Ratio